SBIO ETF Price & Analysis
SBIO ETF Chart & Stats
$48.33
--
Market closed
$48.33
--
Day’s Range― - ―
52-Week Range$22.33 - $54.79
Previous Close$48.33
VolumeN/A
Average Volume (3M)37.82K
AUM131.56M
NAV49.51
Expense Ratio0.50%
Holdings Count87
Beta1.15
Inception DateDec 31, 2014
Last Dividend Ex-Date
Dec 19, 2024Dividend Yield
(―)Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. Volume23,640
30 Day Avg. Volume37,822
AlphaN/A
ETF Overview
ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an innovative investment vehicle designed for those looking to capitalize on the dynamic and rapidly evolving biotechnology sector within the broader health care category. This ETF uniquely focuses on small to mid-cap biotechnology companies that are poised at the forefront of medical advancements, particularly those engaged in the development of groundbreaking treatments and therapies. By targeting firms with drugs in Phase II and Phase III clinical trials, SBIO offers exposure to companies on the cusp of delivering potentially transformative health care solutions.
Investors interested in the cutting-edge of medical innovation will appreciate SBIO's strategic approach, which combines focused sector expertise with the potential for high growth. As the global demand for advanced medical treatments continues to rise, this ETF provides a curated portfolio that taps into the heart of scientific discovery and medical progress. With the ALPS Medical Breakthroughs ETF, investors are not just buying into stocks; they are investing in the future of health care and the promise of revolutionary therapies that could redefine medical treatment paradigms.
ALPS Medical Breakthroughs ETF (SBIO) Fund Flow Chart
ALPS Medical Breakthroughs ETF (SBIO) 1 year Net Flows: $2M
SBIO ETF News
SBIO ETF FAQ
What was SBIO’s price range in the past 12 months?
SBIO lowest ETF price was $22.33 and its highest was $54.79 in the past 12 months.
What is the AUM of SBIO?
As of Mar 19, 2026 The AUM of SBIO is 131.56M.
Is SBIO overvalued?
According to Wall Street analysts SBIO’s price is currently Undervalued.
Does SBIO pay dividends?
SBIO pays a Annually dividend of $1.174 which represents an annual dividend yield of N/A. See more information on SBIO dividends here
How many shares outstanding does SBIO have?
Currently, no data Available
Which hedge fund is a major shareholder of SBIO?
Currently, no hedge funds are holding shares in SBIO
SBIO ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Kymera Therapeutics, Inc.
4.22%
CG Oncology, Inc.
3.65%
Mirum Pharmaceuticals
3.55%
Celcuity Inc.
3.26%
Alkermes plc
3.11%
Xenon Pharmaceuticals
3.03%
Amicus Therapeutics
3.01%
Viking Therapeutics
2.48%
Crinetics Pharma
2.47%
Apogee Therapeutics, Inc.
2.45%
Total31.23%
See All Holdings


